{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:59:05Z","timestamp":1772009945213,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RU 5211 SOMACROSS"],"award-info":[{"award-number":["RU 5211 SOMACROSS"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR2690 PruSearch"],"award-info":[{"award-number":["FOR2690 PruSearch"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01615-8","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:05:15Z","timestamp":1765623915000},"page":"977-992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Preferences Among Systemic Therapy-Na\u00efve Patients with Atopic Dermatitis or Psoriasis in Germany: A Multicentre Study"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-959X","authenticated-orcid":false,"given":"Svenja","family":"Royeck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Daphne","family":"Bamidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Weckbecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4221-386X","authenticated-orcid":false,"given":"Silke C.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-3867","authenticated-orcid":false,"given":"Natalija","family":"Novak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-9832","authenticated-orcid":false,"given":"Galina","family":"Balakirski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-7192","authenticated-orcid":false,"given":"Dagmar","family":"Wilsmann-Theis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, Kobyletzki LB, Svalstedt M, Svensson \u00c5. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100:adv00160.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1615_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol"},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/all.15818","volume":"79","author":"S Cameron","year":"2024","unstructured":"Cameron S, Donnelly A, Broderick C, et al. Mind and skin: exploring the links between inflammation, sleep disturbance and neurocognitive function in patients with atopic dermatitis. Allergy. 2024;79:26\u201336.","journal-title":"Allergy"},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jdv.20258","volume":"39","author":"L Gether","year":"2025","unstructured":"Gether L, Linares HPI, Kezic S, et al. Skin and systemic inflammation in adults with atopic dermatitis before and after whole-body topical betamethasone 17-valerate 0.1% or tacrolimus 0.1% treatment: a randomized controlled study. J Eur Acad Dermatol Venereol. 2025;39:308\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","volume":"19","author":"A Paller","year":"2018","unstructured":"Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821\u201338.","journal-title":"Am J Clin Dermatol"},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","volume":"86","author":"DMR Davis","year":"2022","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86:1335-1336.e18.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1615_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","volume":"25","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P. Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol. 2024;25(4):527\u201340.","journal-title":"Am J Clin Dermatol"},{"key":"1615_CR8","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.6485","volume":"103","author":"S Van Beugen","year":"2023","unstructured":"Van Beugen S, Schut C, Kupfer J, et al. Perceived stigmatization among dermatological outpatients compared with controls: an observational multicentre study in 17 European countries. Acta Derm Venereol. 2023;103:adv6485.","journal-title":"Acta Derm Venereol"},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1615_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/jdv.14007","volume":"31","author":"L Puig","year":"2017","unstructured":"Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31:213\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"1615_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/jdv.18751","volume":"37","author":"A Bewley","year":"2023","unstructured":"Bewley A, van de Kerkhof P. Engaging psoriasis patients in adherence and outcomes to topical treatments: a summary from the Symposium \u201cTailoring topical psoriasis treatments to patients\u201d needs and expectations\u2019 of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023;37(Suppl 1):9\u201313.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41573-023-00735-0","volume":"22","author":"T Bieber","year":"2023","unstructured":"Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22:662\u201380.","journal-title":"Nat Rev Drug Discov"},{"key":"1615_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13555-021-00635-4","volume":"12","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12:61\u201378.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1615_CR14","first-page":"189","volume":"15","author":"C Kromer","year":"2017","unstructured":"Kromer C, Peitsch WK, Herr R, et al. Behandlungspr\u00e4ferenzen f\u00fcr Biologika bei Psoriasis: erfahrene Patienten legen Wert auf Nachhaltigkeit. J Dtsch Dermatol Ges. 2017;15:189\u2013201.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1615_CR15","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.24339","volume":"104","author":"M Ameen","year":"2024","unstructured":"Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024;104:adv24339.","journal-title":"Acta Derm Venereol"},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","volume":"79","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy. 2024;79:1501\u201315.","journal-title":"Allergy"},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583\u201396.","journal-title":"Lancet"},{"key":"1615_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041312","volume":"14","author":"RC Yi","year":"2025","unstructured":"Yi RC, Akbik M, Smith LR, Klionsky Y, Feldman SR. Therapeutic advancements in psoriasis and psoriatic arthritis. J Clin Med. 2025;14:1312.","journal-title":"J Clin Med"},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/bjd\/ljaf166","volume":"193","author":"AM Drucker","year":"2025","unstructured":"Drucker AM, Walwyn C, Chu C, et al. Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. Br J Dermatol. 2025;193:548\u201352.","journal-title":"Br J Dermatol"},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jaad.2024.10.076","volume":"92","author":"LK Ferris","year":"2025","unstructured":"Ferris LK, Bagel J, Huang Y-H, et al. FRONTIER-2: a phase\u00a02b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2025;92:495\u2013502.","journal-title":"J Am Acad Dermatol"},{"key":"1615_CR21","doi-asserted-by":"publisher","first-page":"1574697","DOI":"10.3389\/fmed.2025.1574697","volume":"12","author":"A Chiricozzi","year":"2025","unstructured":"Chiricozzi A, Levi A, Palladino C, Girolomoni G. Enabling precision medicine with biomarkers of response to treatment in atopic dermatitis: where are we now? A narrative review. Front Med (Lausanne). 2025;12:1574697.","journal-title":"Front Med (Lausanne)"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jid.2023.04.005","volume":"143","author":"RD Mortlock","year":"2023","unstructured":"Mortlock RD, Ma EC, Cohen JM, Damsky W. Assessment of treatment-relevant immune biomarkers in psoriasis and atopic dermatitis: toward personalized medicine in dermatology. J Investig Dermatol. 2023;143:1412\u201322.","journal-title":"J Investig Dermatol"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.23736\/S2784-8671.23.07568-0","volume":"158","author":"L Degli Esposti","year":"2023","unstructured":"Degli Esposti L, Perrone V, Dovizio M, et al. Estimation of patients with psoriasis potentially eligible and currently untreated with biological drugs in Italy. Ital J Dermatol Venereol. 2023;158:445\u201351.","journal-title":"Ital J Dermatol Venereol"},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.19465","volume":"38","author":"A Heratizadeh","year":"2024","unstructured":"Heratizadeh A, Mempel M, Kiedrowski R, et al. Checklist identification of candidates for systemic therapy in adult patients with atopic dermatitis in Germany: a multicentre study. J Eur Acad Dermatol Venereol. 2024;38:157\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00105-021-04913-2","volume":"73","author":"M Augustin","year":"2022","unstructured":"Augustin M, Garbe C, Neitemeier S, et al. Regionale Variationen in der Versorgung von Patienten mit Psoriasis und atopischer Dermatitis in Deutschland. Hautarzt. 2022;73:27\u201339.","journal-title":"Hautarzt"},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E Von Elm","year":"2007","unstructured":"Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"1615_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7640314","volume":"2021","author":"HN Cheung","year":"2021","unstructured":"Cheung HN, Chan YS, Hsiung NH. Validation of the 5-D itch scale in three ethnic groups and exploring optimal cutoff values using the itch numerical rating scale. Biomed Res Int. 2021;2021:7640314.","journal-title":"Biomed Res Int"},{"key":"1615_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2016.01466","volume":"7","author":"AM Boonstra","year":"2016","unstructured":"Boonstra AM, Stewart RE, K\u00f6ke AJA, et al. Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol. 2016;7:1466.","journal-title":"Front Psychol"},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316\u201321.","journal-title":"Br J Dermatol"},{"key":"1615_CR31","first-page":"934","volume":"19","author":"A Nast","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, et al. German S3-guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm\u2014part 1: treatment goals and treatment recommendations. JDDG J Dtsch Dermatol Ges. 2021;19:934\u2013150.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1615_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13223-025-00961-8","volume":"21","author":"M Herzig","year":"2025","unstructured":"Herzig M, vom Hove M, Bertsche A, et al. Medication-related perceptions of children and adolescents with severe asthma and moderate-to-severe atopic dermatitis: a non-interventional exploratory study. Allergy Asthma Clin Immunol. 2025;21:16.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1615_CR33","doi-asserted-by":"publisher","first-page":"1367099","DOI":"10.3389\/fimmu.2024.1367099","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Ding R-L, Bu J. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review. Front Immunol. 2024;15:1367099.","journal-title":"Front Immunol"},{"key":"1615_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/19417381221076470","volume":"15","author":"DM Cushman","year":"2023","unstructured":"Cushman DM, Kobayashi JK, Wheelwright JC, et al. Prospective evaluation of pain flares and time until pain relief following musculoskeletal corticosteroid injections. Sports Health. 2023;15:227\u201333.","journal-title":"Sports Health"},{"key":"1615_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2147\/CCID.S400679","volume":"16","author":"M Megna","year":"2023","unstructured":"Megna M, Battista T, Noto M, et al. Injections site reactions and biologics for psoriasis: a questionnaire based real life study. Clin Cosmet Investig Dermatol. 2023;16:553\u201364.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1615_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jan.13818","volume":"75","author":"J McLenon","year":"2019","unstructured":"McLenon J, Rogers MAM. The fear of needles: a systematic review and meta-analysis. J Adv Nurs. 2019;75:30\u201342.","journal-title":"J Adv Nurs"},{"key":"1615_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058799","volume":"12","author":"C Thomas","year":"2022","unstructured":"Thomas C, Raibouaa A, Wollenberg A, et al. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment. BMJ Open. 2022;12:e058799.","journal-title":"BMJ Open"},{"key":"1615_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"1615_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297","volume":"18","author":"K R\u00f8nholt","year":"2017","unstructured":"R\u00f8nholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18:2297.","journal-title":"Int J Mol Sci"},{"key":"1615_CR40","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2308682","volume":"35","author":"M-L Schaarschmidt","year":"2024","unstructured":"Schaarschmidt M-L, Kromer D, Wellmann P, Peitsch WK, Kromer C. Patients\u2019 preferences for systemic treatment of atopic dermatitis: safety and efficacy count the most. J Dermatol Treat. 2024;35:2308682.","journal-title":"J Dermatol Treat"},{"key":"1615_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00403-021-02321-z","volume":"315","author":"LEMde Wijs","year":"2023","unstructured":"Wijs LEMde, van Egmond S, Devillers ACA, Nijsten T, Hijnen D, Lugtenberg M. Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study. Arch Dermatol Res. 2023;315:75\u201383.","journal-title":"Arch Dermatol Res"},{"key":"1615_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","volume":"59","author":"M-EF Mohamed","year":"2020","unstructured":"Mohamed M-EF, Kl\u00fcnder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2020;59:531\u201344.","journal-title":"Clin Pharmacokinet"},{"key":"1615_CR43","unstructured":"Professional Information Lebrikizumab (accessed online on 2 November 2025). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20231116160693\/anx_160693_de.pdf."},{"key":"1615_CR44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.anai.2025.02.017","volume":"134","author":"JS LeBovidge","year":"2025","unstructured":"LeBovidge JS, Schneider LC. Depression and anxiety in patients with atopic dermatitis: recognizing and addressing mental health burden. Ann Allergy Asthma Immunol. 2025;134:506\u201315.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1615_CR45","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/jdv.19913","volume":"38","author":"C Zeidler","year":"2024","unstructured":"Zeidler C, Kupfer J, Dalgard FJ, et al. Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: results from a European multi-centre study. J Eur Acad Dermatol Venereol. 2024;38:1649\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR46","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609\u201321.","journal-title":"Patient Prefer Adherence"},{"key":"1615_CR47","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42773","volume":"105","author":"S M\u00fcller","year":"2025","unstructured":"M\u00fcller S, Zeidler C, Mess C, et al. Patient needs and treatment goals in chronic atopic pruritus: does eczema make a difference? Acta Derm Venereol. 2025;105:adv42773.","journal-title":"Acta Derm Venereol"},{"key":"1615_CR48","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/jdv.15712","volume":"33","author":"S St\u00e4nder","year":"2019","unstructured":"St\u00e4nder S, Yosipovitch G, Bushmakin AG, et al. Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole. J Eur Acad Dermatol Venereol. 2019;33:1742\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR49","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2340\/00015555-2263","volume":"96","author":"SE Marron","year":"2016","unstructured":"Marron SE, Tomas-Aragones L, Boira S, Campos-Rodenas R. Quality of life, emotional wellbeing and family repercussions in dermatological patients experiencing chronic itching: a pilot study. Acta Derm Venereol. 2016;96:331\u20135.","journal-title":"Acta Derm Venereol"},{"key":"1615_CR50","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR51","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1346-8138.16703","volume":"50","author":"Y Tada","year":"2023","unstructured":"Tada Y, Itakura A, Hosono K, Kawamura T. Psoriasis patient preferences for the use of biologics during the coronavirus era. J Dermatol. 2023;50:596\u2013607.","journal-title":"J Dermatol"},{"key":"1615_CR52","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/24755303241253200","volume":"9","author":"M Zaino","year":"2024","unstructured":"Zaino M, Parks E, McNeil J, Feldman S. Patients\u2019 preferences regarding modes of systemic psoriasis treatment\u2014a qualitative study. J Psoriasis Psoriatic Arthritis. 2024;9:136\u201342.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1615_CR53","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/bjd.15086","volume":"176","author":"RJ Thorneloe","year":"2017","unstructured":"Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis. Br J Dermatol. 2017;176:667\u201376.","journal-title":"Br J Dermatol"},{"key":"1615_CR54","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1615_CR55","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jaip.2021.02.027","volume":"9","author":"L Maintz","year":"2021","unstructured":"Maintz L, Bieber T, Bissonnette R, Jack C. Measuring atopic dermatitis disease severity: the potential for electronic tools to benefit clinical care. J Allergy Clin Immunol Pract. 2021;9:1473-1486.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1615_CR56","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/bjd.13691","volume":"172","author":"H Kitchen","year":"2015","unstructured":"Kitchen H, Cordingley L, Young H, Griffiths CEM, Bundy C. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! Br J Dermatol. 2015;172:1210\u201321.","journal-title":"Br J Dermatol"},{"key":"1615_CR57","first-page":"337","volume":"160","author":"M Maurelli","year":"2025","unstructured":"Maurelli M, Gisondi P, Girolomoni G. Gender perspective in the management of psoriasis. Ital J Dermatol Venerol. 2025;160:337\u201343.","journal-title":"Ital J Dermatol Venerol"},{"key":"1615_CR58","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1067\/mjd.2000.101596","volume":"42","author":"RS Hotard","year":"2000","unstructured":"Hotard RS, Feldman SR, Fleischer AB. Sex-specific differences in the treatment of severe psoriasis. J Am Acad Dermatol. 2000;42:620\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"1615_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129120","volume":"10","author":"C Kromer","year":"2015","unstructured":"Kromer C, Schaarschmidt M-L, Schmieder A, Herr R, Goerdt S, Peitsch WK. Patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment. PLoS ONE. 2015;10:e0129120.","journal-title":"PLoS ONE"},{"key":"1615_CR60","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/09546634.2017.1341609","volume":"29","author":"ME Kubin","year":"2018","unstructured":"Kubin ME, P\u00e4\u00e4kk\u00f6 TJW, H\u00e4gg PM, Tasanen K, Palatsi R. Patients with male gender or greater body weight use smaller amounts of topical therapy in psoriasis. J Dermatolog Treat. 2018;29:109\u201310.","journal-title":"J Dermatolog Treat"},{"key":"1615_CR61","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Investig Dermatol. 2015;135:984\u201391.","journal-title":"J Investig Dermatol"},{"key":"1615_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40257-023-00818-z","volume":"25","author":"S M\u00fcller","year":"2024","unstructured":"M\u00fcller S, Zeidler C, St\u00e4nder S. Chronic prurigo including prurigo nodularis: new insights and treatments. Am J Clin Dermatol. 2024;25:15\u201333.","journal-title":"Am J Clin Dermatol"},{"key":"1615_CR63","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2020.08.032","volume":"84","author":"RG Langley","year":"2021","unstructured":"Langley RG, Poulin Y, Srivastava B, et al. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol. 2021;84:60\u20139.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01615-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01615-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:04:48Z","timestamp":1772006688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01615-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01615-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Svenja Royeck was an advisor, speaker or investigator for Almirall, Incyte Inc., Eli Lilly, LEO Pharma and Sanofi\/Regeneron outside the submitted work. Anna Daphne Bamidis has no conflicts of interest to declare. Conrad Weckbecker has no conflicts of interest to declare. Silke C. Hofmann has been an advisor, speaker or investigator for Amgen, Galderma, Janssen-Cilag, Novartis, Infectopharm, and GSK. Sonja St\u00e4nder was speaker and\/or consultant and\/or Investigator and\/or has received research funding from Amgen Inc., Almirall S. A., Celldex Therapeutics Inc., Clexio Biosciences Ltd., Focus-Insight Healthtech Group Co. Ltd., Galderma Laboratorium GmbH, Galderma R & D, LLC., Galderma SA, Klirna Biotech Inc., GSK R&D Ltd., Incyte Corporation, LEO Pharma GmbH, Lilly Deutschland GmbH, Novartis Pharma GmbH, P. G. Unna Academy, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R& D, Sanofi Genzyme Corporation, TouchIME, Vifor Pharma Deutschland GmbH. Sonja St\u00e4nder is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Sonja St\u00e4nder was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Natalija Novak has been an advisor, speaker or investigator for Abbvie, Alk Abello, Almirall, Bencard Allergy Therapeutics, Blueprint, Biogen, Bristol-Myers Squibb, DocCheck, Eli Lilly, Galderma, HAL Allergie, Incyte, Leo Pharma, Janssen, Leti Pharma, Lofarma, Moonlake, Novartis, Phadia, Regenoron, Sanofi Genzyme, Stallergenes Greer, Streamed up, Thermo Fisher Scientific, UCB. Galina Balakirski has been an advisor, speaker or investigator for Abbvie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galderma, Infectopharm, Janssen-Cilag, Leo Pharma, MoonLake Immunotherapeutics, Novartis, Pfizer, Sanofi, UCB Pharma. Dagmar Wilsmann-Theis has been an advisor, speaker or investigator for Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Hexal, Incyte, Janssen-Cilag, Leo Pharma, Eli Lilly, Medac, Merck Sharp & Dohme Corp., Moonlake Immunotherapeutics, Novartis, Pfizer and UCB Pharma. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study received approval from the Ethics Committee at the Medical Faculty Bonn, Germany (approval 2022\u201353-BO) and the Ethics Committee at the University Witten\/Herdecke (approval 46\/2023). The study was conducted in accordance with the Declaration of Helsinki of 1964 and its later amendments. Informed consent to participate was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}